Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Lilly triple-G bet sees 16.8% weight loss in ph. 3 diabetes test
Eli Lilly is rounding out its pitch for retatrutide with new data looking at blood sugar reductions and weight loss in patients with Type 2 diabetes.
Fraiser Kansteiner
Mar 19, 2026 6:45am
Novo Holdings assets shrink by 3rd as Novo Nordisk shares fall
Mar 12, 2026 7:15am
Novo Nordisk inks $2.1B oral drug delivery pact
Feb 25, 2026 8:00am
Novo's triple G candidate drives 20% weight loss in phase 2
Feb 24, 2026 7:42am
Novo's CagriSema loses phase 3 obesity battle against Zepbound
Feb 23, 2026 7:20am
Kailera, Hengrui to advance oral obesity drug into 2 new trials
Feb 10, 2026 9:25am
